Home » Newsletters » BioWorld Science

BioWorld Science

July 27, 2010

View Archived Issues

Achillion selects ACH-2928 as lead candidate against HCV infection

Clinical phase III data presented on linagliptin in type 2 diabetes

IL-7 gene SNPs correlate with rapid HPV clearance in HIV-1-infected subjects

KIF5A, CD226 and SH2B3 gene variants linked to autoimmune diseases

New PET tracer [18F]-MK-3328 for AD diagnosis advances in phase I trial

Genticel's phase I ProCervix trial in HPV-infected women cleared in Belgium

Cytokinetics receives NINDS grant for CK-2017357 development

Tibotec submits NDA for HIV therapeutic TMC-278 to FDA

Onyx presents phase IIb data on carfilzomib in multiple myeloma

FDA grants orphan drug status to BiovaxID for mantle cell lymphoma

Prana Biotechnology claims new quinazolinones for PD

AVEO pays XOMA milestone after starting phase II AV-299 trial

Xenon Pharma discloses new voltage-gated sodium channel blockers

Health Canada clears phase II iCo-007 trial in diabetic macular edema

Canadian scientists discover new agents to deliver antineoplastic therapy

Arena identifies novel prostanoid IP1 receptor agonists

U.S. researchers present new PKR1/PKR2 receptor antagonists

FDA approves Daiichi Sankyo's Tribenzor for hypertension

Titan Pharma receives NIH grant to develop long-term PD therapy

Ampio completes negotiations to acquire DMI BioSciences

QRxPharma to submit MAA for MoxDuo IR analgesic in Germany

CF-102 decreases HCV load in phase I/II trial in liver cancer

FDA posts briefing materials on AstraZeneca's ticagrelor NDA

CHMP issues positive opinion on Arixtra use for superficial vein thrombosis

FIT-06 shows promise in treatment-naive HIV-1-infected subjects

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...